A phase II/III randomised, double blinded, placebo controlled trial of gemcitabine/ [+] carboplatin with or without thalidomide in advanced non-small cell lung cancer.

Trial Profile

A phase II/III randomised, double blinded, placebo controlled trial of gemcitabine/ [+] carboplatin with or without thalidomide in advanced non-small cell lung cancer.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Thalidomide (Primary) ; Carboplatin
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Sep 2009 Primary endpoint 'Overall survival' has not been met according to results published in the Journal of Clinical Oncology.
    • 21 Sep 2009 Results published online by the Journal of Clinical Oncology.
    • 21 Sep 2009 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top